The impact of psychostimulant use on office based buprenorphine treatment retention
Abstract Background Over a million people have died from overdose since 1999, over 600,000. of which involved opioids. Treatment options that focus on overdose prevention are desperately needed and buprenorphine treatment is a form of opioid prevention if provided in a harm reduction setting. Co-mor...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-04-01
|
| Series: | Harm Reduction Journal |
| Online Access: | https://doi.org/10.1186/s12954-025-01201-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850184506247479296 |
|---|---|
| author | Ryan Edgerton Peter Rebeiro Sam MacMaster Lisa Bell Parul Patel Loren Ginn Kyra Beach Veeraj Shah R. Lyle Cooper |
| author_facet | Ryan Edgerton Peter Rebeiro Sam MacMaster Lisa Bell Parul Patel Loren Ginn Kyra Beach Veeraj Shah R. Lyle Cooper |
| author_sort | Ryan Edgerton |
| collection | DOAJ |
| description | Abstract Background Over a million people have died from overdose since 1999, over 600,000. of which involved opioids. Treatment options that focus on overdose prevention are desperately needed and buprenorphine treatment is a form of opioid prevention if provided in a harm reduction setting. Co-morbid opioid and stimulant use disorders have increased at a higher rate than other co-morbid combinations between 2011 and 2019. The objective of this study was to identify the effects of psychostimulant use on buprenorphine treatment retention. Methods We conducted an analysis of a cohort of 143 individuals with opioid use disorder that initiated treatment in a low-threshold, urban office based opioid treatment (OBOT) clinic located in Nashville Tennessee between 2018 and 2020. Retention was measured at 1, 3, and 6-months. Logistic regression was used to identify differences between people who tested positive for stimulants and people who did not. Results The majority of the patients were white (83%), male (64%), unhoused (59%) and uninsured (70%). There was moderate psychostimulant use in the sample with 19% testing positive for cocaine and 13% testing positive for methamphetamine at baseline. Patients testing positive for cocaine prior to their six month retention point had 0.279 lower odds of being retained in treatment. Further, testing positive for either cocaine or methamphetamine resulted in 0.284 and 0.258 odds of retention at 3 and 6-months respectively. Conclusion This study examined the impact of stimulant use on retention in buprenorphine treatment within a low-threshold OBOT clinic. Our findings differ from previous research that reported significant decreases in retention among methamphetamine users. Instead, results suggest that patients using psychostimulants can be effectively retained in care within a low-resource, low-threshold setting, though increased clinical engagement may be beneficial for those testing positive for cocaine or methamphetamine. Given the limited access to buprenorphine treatment, these findings underscore the urgent need for expanded, accessible treatment models that can effectively serve individuals with co-occurring stimulant use. |
| format | Article |
| id | doaj-art-a4d29fdcc41c4c949ad4e6fd2542721a |
| institution | OA Journals |
| issn | 1477-7517 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | BMC |
| record_format | Article |
| series | Harm Reduction Journal |
| spelling | doaj-art-a4d29fdcc41c4c949ad4e6fd2542721a2025-08-20T02:17:01ZengBMCHarm Reduction Journal1477-75172025-04-012211710.1186/s12954-025-01201-3The impact of psychostimulant use on office based buprenorphine treatment retentionRyan Edgerton0Peter Rebeiro1Sam MacMaster2Lisa Bell3Parul Patel4Loren Ginn5Kyra Beach6Veeraj Shah7R. Lyle Cooper8Meharry Medical College NashvilleVanderbilt University Medical CenterMeharry Medical College NashvilleMeharry Medical College NashvilleMeharry Medical College NashvilleMeharry Medical College NashvilleUniversity of Texas Health Science CenterVanderbilt UniversityMeharry Medical College NashvilleAbstract Background Over a million people have died from overdose since 1999, over 600,000. of which involved opioids. Treatment options that focus on overdose prevention are desperately needed and buprenorphine treatment is a form of opioid prevention if provided in a harm reduction setting. Co-morbid opioid and stimulant use disorders have increased at a higher rate than other co-morbid combinations between 2011 and 2019. The objective of this study was to identify the effects of psychostimulant use on buprenorphine treatment retention. Methods We conducted an analysis of a cohort of 143 individuals with opioid use disorder that initiated treatment in a low-threshold, urban office based opioid treatment (OBOT) clinic located in Nashville Tennessee between 2018 and 2020. Retention was measured at 1, 3, and 6-months. Logistic regression was used to identify differences between people who tested positive for stimulants and people who did not. Results The majority of the patients were white (83%), male (64%), unhoused (59%) and uninsured (70%). There was moderate psychostimulant use in the sample with 19% testing positive for cocaine and 13% testing positive for methamphetamine at baseline. Patients testing positive for cocaine prior to their six month retention point had 0.279 lower odds of being retained in treatment. Further, testing positive for either cocaine or methamphetamine resulted in 0.284 and 0.258 odds of retention at 3 and 6-months respectively. Conclusion This study examined the impact of stimulant use on retention in buprenorphine treatment within a low-threshold OBOT clinic. Our findings differ from previous research that reported significant decreases in retention among methamphetamine users. Instead, results suggest that patients using psychostimulants can be effectively retained in care within a low-resource, low-threshold setting, though increased clinical engagement may be beneficial for those testing positive for cocaine or methamphetamine. Given the limited access to buprenorphine treatment, these findings underscore the urgent need for expanded, accessible treatment models that can effectively serve individuals with co-occurring stimulant use.https://doi.org/10.1186/s12954-025-01201-3 |
| spellingShingle | Ryan Edgerton Peter Rebeiro Sam MacMaster Lisa Bell Parul Patel Loren Ginn Kyra Beach Veeraj Shah R. Lyle Cooper The impact of psychostimulant use on office based buprenorphine treatment retention Harm Reduction Journal |
| title | The impact of psychostimulant use on office based buprenorphine treatment retention |
| title_full | The impact of psychostimulant use on office based buprenorphine treatment retention |
| title_fullStr | The impact of psychostimulant use on office based buprenorphine treatment retention |
| title_full_unstemmed | The impact of psychostimulant use on office based buprenorphine treatment retention |
| title_short | The impact of psychostimulant use on office based buprenorphine treatment retention |
| title_sort | impact of psychostimulant use on office based buprenorphine treatment retention |
| url | https://doi.org/10.1186/s12954-025-01201-3 |
| work_keys_str_mv | AT ryanedgerton theimpactofpsychostimulantuseonofficebasedbuprenorphinetreatmentretention AT peterrebeiro theimpactofpsychostimulantuseonofficebasedbuprenorphinetreatmentretention AT sammacmaster theimpactofpsychostimulantuseonofficebasedbuprenorphinetreatmentretention AT lisabell theimpactofpsychostimulantuseonofficebasedbuprenorphinetreatmentretention AT parulpatel theimpactofpsychostimulantuseonofficebasedbuprenorphinetreatmentretention AT lorenginn theimpactofpsychostimulantuseonofficebasedbuprenorphinetreatmentretention AT kyrabeach theimpactofpsychostimulantuseonofficebasedbuprenorphinetreatmentretention AT veerajshah theimpactofpsychostimulantuseonofficebasedbuprenorphinetreatmentretention AT rlylecooper theimpactofpsychostimulantuseonofficebasedbuprenorphinetreatmentretention AT ryanedgerton impactofpsychostimulantuseonofficebasedbuprenorphinetreatmentretention AT peterrebeiro impactofpsychostimulantuseonofficebasedbuprenorphinetreatmentretention AT sammacmaster impactofpsychostimulantuseonofficebasedbuprenorphinetreatmentretention AT lisabell impactofpsychostimulantuseonofficebasedbuprenorphinetreatmentretention AT parulpatel impactofpsychostimulantuseonofficebasedbuprenorphinetreatmentretention AT lorenginn impactofpsychostimulantuseonofficebasedbuprenorphinetreatmentretention AT kyrabeach impactofpsychostimulantuseonofficebasedbuprenorphinetreatmentretention AT veerajshah impactofpsychostimulantuseonofficebasedbuprenorphinetreatmentretention AT rlylecooper impactofpsychostimulantuseonofficebasedbuprenorphinetreatmentretention |